AQST News and Press, Aquestive Therapeutics Inc.

WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the...

2026-06-04 17:00:10 ET Investment Overview: Update Since My Last Post - Anaphylm Denied FDA Approval The last time I covered Aquestive Therapeutics, Inc. ( AQST ) in a note for Seeking Alpha, it was September 2025 , and the Warren, New Jersey-headquartered biotech's stock ha...

2026-05-30 23:31:08 ET ... Read the full article on Seeking Alpha For further details see: Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right

2026-05-14 14:18:05 ET Image source: The Motley Fool. Thursday, May 14, 2026 at 8:00 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-14 11:10:07 ET More on Aquestive Therapeutics Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript Aquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation ...

2026-05-14 11:07:09 ET Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

2026-05-13 16:06:14 ET More on Aquestive Therapeutics Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript ...

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026 Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United Kingdom Completed AQST-108 phase 1 study in subjects with androgeni...

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologi...

WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologi...